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Abstract
Suicide is a serious public health concern, and it is partly genetic. The brain-derived neurotrophic 
factor (BDNF) gene has been a strong candidate in genetic studies of suicide (Zai et al, 2012; 
Dwivedi et al, 2010) and BDNF regulates the expression of the dopamine D3 receptor.
Objective—We examined the role of the BDNF and DRD3 genes in suicide.
Methods—We analyzed four tag single-nucleotide polymorphisms (SNPs) in BDNF and 15 
SNPs in the D3 receptor gene DRD3 for possible association with suicide attempt history in our 
Canadian sample of Schizophrenia (SCZ) patients of European ancestry (N=188).
Results—In this sample, we found a possible interaction between the BDNF Val66Met and 
DRD3 Ser9Gly SNPs in increasing the risk of suicide attempt(s) in our SCZ sample. Specifically, 
a larger proportion of SCZ patients who were carrying at least one copy of the minor allele at each 
of the Val66Met and Ser9Gly functional markers have attempted suicides compared to patients 
with other genotypes (Bonferroni p<0.05). However, we could not replicate this finding in 
samples from other psychiatric populations.
Conclusions—Taken together, the results from the present study suggest that an interaction 
between BDNF and DRD3 may not play a major role in the risk for suicide attempt, though further 
studies, especially in SCZ, are required.
Keywords
Schizophrenia; dopamine receptor DRD3; brain-derived neurotrophic factor BDNF; genetics; 
suicidal behaviour
2 INTRODUCTION
Suicides claim one million lives worldwide each year. They account for approximately 10% 
of deaths in schizophrenia (SCZ) patients (Meltzer and Baldessarini 2003). A meta-analysis 
of excess mortality rates in SCZ by Brown (Brown 1997) found suicides to be the leading 
cause of excess deaths in SCZ, accounting for 28% of the excess SCZ deaths. Twin studies 
support a genetic basis of suicidal behaviour (Voracek and Loibl 2007).
Reduced brain-derived neurotrophic factor (BDNF) levels have been observed in suicide 
attempters (Deveci et al. 2007; Kim et al. 2007) as well as suicide victims (Dwivedi et al. 
2003; Karege et al. 2005; Pandey et al. 2008). Our recent systematic synthesis of data 
documented that the low-functioning Met allele confer an overall risk for suicide (Zai et al. 
2012).
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BDNF plays a critical role in dopaminergic neuronal establishment (Baquet et al. 2005). The 
number of tyrosine hydroxylase-expressing dopaminergic neurons was reduced in the 
murine midbrain-hindbrain regions where the BDNF gene was selectively deleted (Baquet et 
al. 2005). BDNF also specifically regulates the in vivo expression of dopamine D3 receptor 
(DRD3) in the nucleus accumbens both during development and in adulthood (Guillin et al. 
2001). The DRD3 gene has not been investigated in suicide. Nonetheless, a Taiwanese study 
reported an interaction between BDNF Val66Met and the functional DRD3 Ser9Gly 
polymorphism in susceptibility for bipolar disorder with comorbid anxiety disorder (Chang 
et al. 2013), where comorbid anxiety disorder increased the risk of suicidal behaviour 
(Hawgood and De Leo 2008).
In spite of gene expression and genetic association studies pointing towards a possible role 
of the BDNF gene in suicidal behaviour, the combined role of BDNF and DRD3 in suicidal 
behaviour in SCZ patients has not been studied. In a previous study, we tested for the 
possibility of an association of tag polymorphisms in the DRD3 and BDNF genes with SCZ 
(Zai et al. 2010). Here, we aim to follow up with a study of whether these polymorphisms 
are associated with history of suicide attempt in our sample of SCZ patients. In view of the 
evidences that point to a functional relationship between DRD3 and BDNF, we also aim to 
examine their single-marker interactions in suicide attempt. Finally, we postulate that 
genetic susceptibility to suicidal behaviour may act across diagnostic boundaries; thus we 
aim to examine the significant interactions that are observed in our SCZ sample in 
independent samples including psychiatric patients with bipolar disorder, major depression, 
or bulimia nervosa. This cross-disorder approach has gained recent attention in genome wide 
association studies of complex psychiatric disorders (Lee et al. 2013).
3 PATIENTS AND METHODS
3.1 Subjects
Discovery Schizophrenia sample – TS—The research participants in the Discovery 
Schizophrenia TS sample (N=203, average age 37.46 +/− 10.44 years, 70.7% males) were 
recruited from the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada. 
We have included only participants of European ancestry, as indicated by self-reported 
ethnicities of grandparents, in this study. The Structured Clinical Interview for DSM-III-
R/IV for Axis I Disorders (SCID-I; (First et al. 1997)) was used as the primary diagnostic 
tool (Maxwell 1992). Patients who satisfied the DSM-IV diagnostic criteria for SCZ or 
schizoaffective disorder were included (Association 1994), while patients with history of 
major neurological disorders, major substance abuse, and head injury with significant loss of 
consciousness were excluded from the study. Based on the SCID-I interview as well as 
examination of medical records, 188 SCZ probands have available suicide data, of which 55 
had at least one suicide attempt during their lifetime up to the date of assessment. The study 
was approved by the CAMH Research Ethics Board.
Replication samples with various psychiatric diagnoses—The first replication 
sample (TB sample; N=192; average age 33.46 +/− 9.04 years; 39% males) consists of 
DSM-III-R/IV-diagnosed Bipolar Disorder participants of European ancestry recruited from 
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CAMH. The characteristics of the overall sample have been reported previously (Lett et al. 
2011; Muller et al. 2011). Within the TB sample, 179 participants (48 had at least one 
suicide attempt) were assessed for suicidal behaviour during the SCID-I interview and the 
information was corroborated by examination of their medical records. The second Bipolar 
Disorder (GBP) sample consists of 267 cases of European ancestry (average age=42.36 +/– 
13.24 years; 39.3% males) recruited from CAMH. The overall sample has been described 
previously (Scott et al. 2009; Xu et al. 2014) and suicidal behaviour was assessed using the 
Scheduled Clinical Assessment in Neuropsychiatry (SCAN). Eighty two GBP participants 
had attempted suicide. The studies for TB and GBP were approved by the Research Ethics 
Board at CAMH. The Bulimia Nervosa (BN) sample consists of cases of European ancestry 
that were described in a previous paper (Yilmaz et al. 2011; Yilmaz et al. 2012). Briefly, the 
BN sample consists of 242 female participants of European ancestry (average age 25.93+/− 
7.00 years) of which 239 were assessed for suicidal behaviour during SCID-I interview. 
Nine of these patients had attempted suicide at least once. The Research Ethics Boards at 
CAMH and University Health Network approved the BN study.
The Norwegian sample has been previously described (Finseth et al. 2013). In brief, a total 
number of 1009 psychiatric patients, including 526 Bipolar Disorder cases (NB sample: 304 
BD I, 197 BD II and 25 BD NOS), 338 Schizophrenia cases (NS sample: 258 schizophrenia, 
24 schizophreniform and 56 schizoaffective), and 145 cases with related psychosis spectrum 
disorders (94 other psychosis (delusional disorder, brief psychotic disorder and psychotic 
disorder NOS), 51 major depressive disorder (MDD)) were included. All of the Norwegian 
samples were of European, the majority Norwegian, ethnicity. The patients were recruited 
through a national Norwegian multicenter study (TOP - BRAIN Study) from several 
psychiatric hospitals and out-patient clinics. All patients met DSM-IV criteria for their 
respective diagnosis using the Structured Clinical Interview for DSM-IV (SCID-I) 
(Association 1994; First et al. 1997).
Life-time history of at least one suicide attempt was assessed in all patients. In 25 % of the 
sample this was obtained by asking the patients to disclose if they had made a serious 
suicide attempt in the past requiring medical attention, emergency room visit or 
hospitalization. In the remaining 75%, suicide attempt was defined as in SCID-I, i.e. a past 
suicide attempt due to depression and thoughts of death. Based on these data the patients 
were grouped dichotomously; suicide attempters and non-attempters. Clinical risk factors of 
SB in the sample have been described in detail previously (Finseth et al. 2012; Mork et al. 
2012; Finseth et al. 2013).
DNA isolation and polymorphism genotyping—For the SCZ, TB, GBP, and BN 
samples, genomic DNA was purified from whole blood samples using non-enzymatic 
method previously described (Lahiri and Nurnberger 1991). Genotyping was done after the 
subjects had completed the follow-up, and all laboratory staff members were blind to suicide 
attempt status. In all, we genotyped 34 DRD3 and 14 BDNF polymorphisms in the discovery 
TS sample, of which 15 DRD3 and 4 BDNF polymorphisms were tagged using Haploview 
using minimum minor allele frequency of 0.2 and an r2 threshold of 0.8. The tag 
polymorphisms were genotyped using either TaqMan SNP genotyping assays (Life 
Technologies Inc.) at CAMH or a microarray platform (Illumina) (Hodgkinson et al. 2008) 
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at the The Centre for Applied Genomics as described previously (Zai et al. 2010). For 
replication of the significant interaction finding, genotyping of the Val66Met and Ser9Gly 
polymorphisms in the TB, GBP, and BN repliation samples were done using TaqMan SNP 
genotyping assays at CAMH.
The Norwegian replication samples were genotyped at Expression Analysis (Durham, NC, 
USA) using the Affymetrix Genome-Wide Human SNP array 6.0 (Affymetrix Inc, Santa 
Clara, CA, USA). Quality control was performed using PLINK (Purcell et al. 2007). Details 
on quality control have been described previously (Finseth et al. 2013).
3.3 Statistical Analyses
Adherence to Hardy-Weinberg equilibrium was determined using the chi-square test in 
Haploview version 4 (Barrett et al. 2005). Analyses of SCZ cases with history of suicide 
attempt versus SCZ cases without were done using Fisher’s Exact Tests both in terms of 
allele frequencies and genotype frequencies. Haplotype analyses were done using 
UNPHASED version 3.1.5 (Dudbridge 2008) for the analysis of history of suicide attempt. 
Haplotypes with frequencies of less than 5% were excluded from the analyses. For multiple-
testing correction, our study of nineteen single-nucleotide polymorphisms was equivalent to 
testing twelve independent markers (Nyholt et al. 2004; Li and Ji 2005). Thus, the 
significance threshold was adjusted to 0.0042. Gene-gene interaction analyses were 
performed using HELIXTREE (GoldenHelix; e.g., (Zai et al. 2008)), and the significant 
analyses (after Bonferroni correction) were validated with the R package Model-Based 
Multifactor Dimensionality Reduction version 2.6 (MB-MDR) (Calle et al. 2010) as well as 
SPSS version 15 (IBM). The significance of the model was determined by running 1000 
permutations. The meta-analysis, which incorporated replication samples, was carried out in 
STATA version 8.
4 RESULTS
4.1 DRD3 and BDNF tag SNPs are not associated with suicidal behaviour in TS patients
Genotypes of the 15 tag DRD3 and four tag BDNF polymorphisms did not differ 
significantly from Hardy-Weinberg equilibrium for the Canadian European TS sample 
(p>0.05). We did not find sex distribution or average age at recruitment to be significantly 
different between TS patients who had attempted suicide and those who had not (p>0.05). 
To test for an association of suicidal behaviour, we compared the allele, genotype, and 
haplotype frequency distributions of TS patients who had had at least one suicide attempt to 
those who had not attempted suicide (Tables 1a, 1b). None of the tested DRD3 and BDNF 
SNPs was associated with suicidality in SCZ.
4.2 BDNF-DRD3 interaction, Suicidal behaviour in SCZ patients
Because of the functional relationship between BDNF and DRD3 in vivo, we performed an 
interaction analysis between BDNF and DRD3 polymorphisms using HELIXTREE (Golden 
Helix Inc., Bozeman, MT). In our previous report, we did not find significant association 
between any BDNF-DRD3 two-marker combinations in SCZ diagnosis (Zai et al. 2010), but 
in the present study, we observed a significant interaction between BDNF Val66Met and 
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DRD3 Ser9Gly in predicting lifetime suicide attempt (Figure 1; Bonferroni p<0.05). The 
results fom MB-MDR were also significant (permutation p=0.003). More specifically, SCZ 
patients who carried at least one copy of each rare variant of the Val66Met (A, Met) and 
Ser9Gly (G, Gly) were over-represented among the suicide attempters than other genotype 
combinations (20/36 or 56% of suicide attempters carrying at least one copy of the rare 
alleles for both markers, versus 35/149 or 23% of non-attempters carrying at least one copy 
of the rare alleles for both markers; OR=4.07; CI: 1.91–8.69).
4.3 Replication of BDNF-DRD3 interaction
We were able to amass a large number of European samples with various psychiatric 
diagnoses (N=1694 total) in an effort to replicate the finding of the significant interaction 
between Ser9Gly and Val66Met that we observed in the TS sample with respect to history of 
suicide attempt. As shown by the forest plot (Figure 2), we were not able to replicate the 
findings in the meta-analysis with or without the discovery TS sample (including TS: OR= 
1.11, 95% confidence interval: 0.85–1.46, P=0.438; excluding TS: OR= 0.92, 95% 
confidence interval: 0.68–1.24, P=0.574).
5 DISCUSSION
This is the first comprehensive association study of DRD3 and BDNF polymorphisms with 
suicide. We did not observe any significant association for single SNPs or haplotypes, but 
we found a significant interaction between the functional polymorphisms Val66Met and 
Ser9Gly in the history of suicide attempt(s) in our SCZ Discovery sample.
As pointed out in the introduction, BDNF has been extensively investigated in SCZ with 
contrasting results (Neves-Pereira et al. 2005; Kanazawa et al. 2007; Squassina et al. 2010). 
Our findings confirmed the negative association of BDNF and SCZ, and discrepancies with 
previous reports of association could be explained by the evidence that BDNF variation is 
associated with psychiatric disorders with a primary affective component (Lencz et al. 
2009), supporting the hypothesis that BDNF could exert a role on subphenotypes of SCZ 
(Schumacher et al. 2005).
The significant interaction between Val66Met and Ser9Gly in modulating the suicidal 
outcome led us to hypothesize that since the BDNF Val66Met Met allele has been associated 
with depression (Strauss et al. 2005; Martinowich et al. 2007; Ribeiro et al. 2007), and 
DRD3 Ser9Gly Gly allele has been associated with impulsivity (Retz et al. 2003), suicide 
attempts may require the interaction between the depressive and impulsive traits (Mann 
2003).
Suicide attempters also appeared to be intolerant to delayed rewards (Liu et al. 2012);
(Dombrovski et al. 2011);(Mathias et al. 2011). Moreover, it could be important to underline 
that testing interaction between polymorphisms of genes could prove the evidence of 
statistic epistasis that underlie the biological epistasis (Moore and Williams 2005). This 
assumption is further bolstered if the statistical interaction is between polymorphisms with 
functional roles, as in our study and gain importance in view of the genetic complexity of a 
neuropsychiatric disease like SCZ and suicidal behaviour, in which the polygenic hypothesis 
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of its biological basis has been widely supported. Therefore, even though BDNF and DRD3 
did not confer significant risk of suicide individually, the combination of the two genes, 
their functional polymorphisms, might be associated with increased suicide susceptibility. 
Even though the HELIXTREE analysis yielded a statistically significant interaction between 
the Ser9Gly and Val66Met SNPs in suicide attempt, we were unable to replicate this finding 
in other psychiatric samples. The discrepant findings could be due to a number of reasons. 
The discovery sample was relatively small; thus the possibility of false-positive finding, 
especially for the gene-gene interaction analysis, could not be ruled out. Our discovery 
sample had over 80% power to detect a genetic effect size of 1.95 to 2.17 for minor allele 
frequencies between 20% and 35% (alpha 0.05, additive model; (Gauderman and Morrison 
2006)). The overall negative finding could also be due to insufficient size of the total sample 
to detect this interaction. Given the genetic architecture of the Norwegian population 
(Passarino et al. 2002), part of the genetic susceptibility of suicide in Norwegians may be 
distinct from that in other European populations. The average age of the BN sample was 
lower than other groups, and many of the BN patients could attempt suicide at a later time. 
In addition, the definition of suicide attempt included nonsuicidal self-injuries in the TS, TB, 
and GBP samples, while only serious suicide attempts were considered in the Norwegian 
samples. Thus, the heterogeneity in the definition of suicide attempt could have hampered 
the comparability of the samples. Moreover, the phenotype of suicide attempt for GBP was 
derived from the suicide severity item of SCAN; it reflects the suicide status during a 
depressive episode, but may not account for lifetime suicide attempt. In addition, the genetic 
components of suicidal behaviour may not overlap among the different psychiatric 
diagnoses (Bertolote and Fleischmann 2002; Harkavy-Friedman et al. 2004). Furthermore, 
factors including alcohol and substance use could have confounded the suicide findings and 
contributed to the heterogeneity of suicidal behaviour.
In summary, although the preliminary finding of a genetic interaction between BDNF and 
DRD3 in suicide attempt from our discovery SCZ sample was not replicated in other 
psychiatric samples (including SCZ), replications in additional independent SCZ samples 
with suicide attempt data are needed before the role of this interaction can be dismissed. The 
current study also encourages further studies of suicidal behaviour using different definitions 
and assessment tools to better decipher the role of these genes in this complex phenotype.
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P-values from analyses of two-marker interactions between BDNF and DRD3 
polymorphisms in association with the history of suicide attempt(s) in our Discovery 
Schizophrenia (TS) sample given by HELIXTREE program. Top left triangle indicates 
significance with the raw p-values, while the bottom right triangle indicates significance 
with Bonferroni adjusted p-values. Note that the interaction between BDNF Val66Met and 
DRD3 Ser9Gly was significant in history of suicide attempt(s). The black marked areas were 
included in the Bonferroni correction, but were not considered for the interaction results.
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Forest plot illustrating the overall effect of the presence of at least one copy of Gly9 and 
Met66 in suicide attempt across multiple psychiatric disorders (TS-M: discovery 
schizophrenia sample – males only; TS-F: discovery schizophrenia sample – females only; 
TBM: first bipolar disorder – males; TB-F: first bipolar disorder – females; GBP-M: second 
bipolar disorder – males; GBP-F: second bipolar disorder – females; BN-F: bulimia nervosa 
– females; NS-M: Norwegian schizophrenia sample – males; NS-F: Norwegian 
schizophrenia sample – females; NB-M: Norwegian bipolar disorder – males; NB-F: 
Norwegian bipolar disorder – females; NMx-M: Norwegian psychosis spectrum – males; 
NMx-F: Norwegian psychosis spectrum – females) in a meta-analysis.
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